_pennystock版 - Vical announces issuance of US patent for cytomegalovirus vaccine |
|---|
|
|
|
|
|
f**********g
发帖数: 2252 | 1 Vical announces issuance of US patent for cytomegalovirus vaccine
34 minutes ago - DTM via Comtex
DatamonitorVical Incorporated, a biopharmaceutical company, has announced
the issuance of US patent covering DNA vaccines for cytomegalovirus, or CMV,
containing specific gene sequences and formulated with Vical's Vaxfectin
adjuvant.
Past development by others of protein-based prophylactic CMV vaccines has
focused on antibody-mediated immune responses against the CMV glycoprotein B
(gB) antigen, which has achieved up to 50% protective efficacy.
The new '112 patent covers DNA vaccines containing codon-optimized versions
of genes encoding gB and CMV phosphoprotein 65 (pp65) antigens, formulated
with Vical's Vaxfectin adjuvant. It adds to Vical's family of patents in the
US and other key regions based on the company's discovery that
administering genetic sequences such as DNA or RNA into the body, without
the use of viral delivery vehicles, may cause expression of the proteins
encoded by the genetic sequences. Vical has additional issued patents
covering the composition and use of the Vaxfectin adjuvant.
http://www.datamonitor.com | f**********g
发帖数: 2252 | 2 Vical announces issuance of US patent for cytomegalovirus vaccine
34 minutes ago - DTM via Comtex
DatamonitorVical Incorporated, a biopharmaceutical company, has announced
the issuance of US patent covering DNA vaccines for cytomegalovirus, or CMV,
containing specific gene sequences and formulated with Vical's Vaxfectin
adjuvant.
Past development by others of protein-based prophylactic CMV vaccines has
focused on antibody-mediated immune responses against the CMV glycoprotein B
(gB) antigen, which has achieved up to 50% protective efficacy.
The new '112 patent covers DNA vaccines containing codon-optimized versions
of genes encoding gB and CMV phosphoprotein 65 (pp65) antigens, formulated
with Vical's Vaxfectin adjuvant. It adds to Vical's family of patents in the
US and other key regions based on the company's discovery that
administering genetic sequences such as DNA or RNA into the body, without
the use of viral delivery vehicles, may cause expression of the proteins
encoded by the genetic sequences. Vical has additional issued patents
covering the composition and use of the Vaxfectin adjuvant.
http://www.datamonitor.com |
|
|
|
|
|
|
